Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 15/20 | 0.79 |
| ▸ | JAK1 | P23458 | 16/20 | 0.72 |
| ▸ | JAK3 | P52333 | 4/20 | 0.72 |
| ▸ | TYK2 | P29597 | 2/20 | 0.62 |
| ▸ | AURKA | O14965 | 1/20 | 0.50 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.50 |
| ▸ | INCENP | Q9NQS7 | 1/20 | 0.50 |
| ▸ | TPX2 | Q9ULW0 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19832255 | 0.93 | JAK2 (0.72) | JAK2JAK1JAK3TYK2 | |
| SCHEMBL19832161 | 0.90 | JAK2 (0.76) | JAK2JAK1JAK3TYK2AURKA | |
| SCHEMBL19831990 | 0.88 | JAK2 (1.00) | JAK2JAK1JAK3TYK2 | |
| SCHEMBL19832004 | 0.86 | JAK2 (0.60) | JAK2JAK1JAK3TYK2AURKA | |
| SCHEMBL19832250 | 0.86 | JAK1 (0.83) | JAK2JAK1JAK3TYK2 | |
| SCHEMBL18975893 | 0.84 | JAK2 (1.00) | JAK2JAK1JAK3TYK2 | |
| SCHEMBL19832256 | 0.83 | JAK2 (0.57) | JAK2JAK1JAK3TYK2AURKA | |
| SCHEMBL19832079 | 0.83 | JAK2 (0.73) | JAK2JAK1JAK3TYK2 | |
| SCHEMBL19832105 | 0.81 | JAK2 (0.88) | JAK2JAK1JAK3TYK2 | |
| SCHEMBL21320444 | 0.80 | JAK1 (1.00) | JAK2JAK1JAK3TYK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190270740-A1 | HETEROCYCLIC COMPOUND AS JAK INHIBITOR, AND SALTS AND THERAPEUTIC USE THEREOF | TIANJIN LONGBOGENE PHARMACEUTICAL CO., LTD. (CN) | 2019-09-05 | — | — | US | claimed |
| EP-3492468-A1 | HETEROCYCLIC COMPOUND AS JAK INHIBITOR, AND SALTS AND THERAPEUTIC USE THEREOF | Tianjin Longbogene Pharmaceutical Co., Ltd. (CN) | 2019-06-05 | — | — | EP | claimed |
| US-11414413-B2 | Heterocyclic compound as JAK inhibitor, and salts and therapeutic use thereof | SUZHOU LONGBIOTECH PHARMACEUTICALS CO., LTD. (CN) | 2022-08-16 | — | — | US | disclosed |
| CN-109790158-B | Heterocyclic compounds as JAK inhibitors, salts of the compounds and therapeutic use thereof | 苏州隆博泰药业有限公司 | 2022-06-24 | — | — | CN | disclosed |
| EP-3492468-B1 | HETEROCYCLIC COMPOUND AS JAK INHIBITOR, AND SALTS AND THERAPEUTIC USE THEREOF | SUZHOU LONGBIOTECH PHARMACEUTICALS CO LTD (CN) | 2022-02-23 | — | — | EP | disclosed |
| EP-3492468-B1 | HETEROCYCLIC COMPOUND AS JAK INHIBITOR, AND SALTS AND THERAPEUTIC USE THEREOF | SUZHOU LONGBIOTECH PHARMACEUTICALS CO LTD (CN) | 2022-02-23 | — | — | EP | disclosed |
| US-20190270740-A1 | HETEROCYCLIC COMPOUND AS JAK INHIBITOR, AND SALTS AND THERAPEUTIC USE THEREOF | TIANJIN LONGBOGENE PHARMACEUTICAL CO., LTD. (CN) | 2019-09-05 | — | — | US | disclosed |
| US-20190270740-A1 | HETEROCYCLIC COMPOUND AS JAK INHIBITOR, AND SALTS AND THERAPEUTIC USE THEREOF | TIANJIN LONGBOGENE PHARMACEUTICAL CO., LTD. (CN) | 2019-09-05 | — | — | US | disclosed |
| EP-3492468-A1 | HETEROCYCLIC COMPOUND AS JAK INHIBITOR, AND SALTS AND THERAPEUTIC USE THEREOF | Tianjin Longbogene Pharmaceutical Co., Ltd. (CN) | 2019-06-05 | — | — | EP | disclosed |
| EP-3492468-A1 | HETEROCYCLIC COMPOUND AS JAK INHIBITOR, AND SALTS AND THERAPEUTIC USE THEREOF | Tianjin Longbogene Pharmaceutical Co., Ltd. (CN) | 2019-06-05 | — | — | EP | disclosed |
| WO-2018019222-A1 | HETEROCYCLIC COMPOUND AS JAK INHIBITOR, AND SALTS AND THERAPEUTIC USE THEREOF | 张文燕 | 2018-02-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190270740-A1 | HETEROCYCLIC COMPOUND AS JAK INHIBITOR, AND SALTS AND THERAPEUTIC USE THEREOF | JAK2, JAK1, JAK3 | JAK2 1/4885JAK1 2/4885JAK3 3/4885 |
| US-11414413-B2 | Heterocyclic compound as JAK inhibitor, and salts and therapeutic use thereof | JAK2, JAK1, JAK3 | JAK2 1/4885JAK1 2/4885JAK3 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.